NEW RIVER PHARMACEUTICALS

The Company

Management

Research & Development

Product Candidates
Investor Relations
Contact Us




TRANSFORMING MEDICINETRANSFORMING MEDICINE
PRODUCTS NRP290 NRP369NRP409

Product Candidates

Our drug development pipeline currently includes four active programs in clinical or preclinical development stages. All of our drug candidates are small molecules designed for oral delivery.

Vyvanse™ (lisdexamfetamine dimesylate, formerly NRP104) is under FDA review for the treatment of ADHD in pediatric populations.

We are developing NRP290 to treat acute pain as an alternative to Lortab®, Vicodin® and Vicoprofen®. NRP290 is intended to be a safer, abuse-resistant and effective alternative to currently marketed opioids. NRP409 is being developed as a replacement or supplemental therapy in patients with primary hypothyroidism and other indications.

NRP369 has been repositioned as a backup to NRP290.

 

This website contains certain trademarks, trade names and service marks of other companies, including Concerta®, Cylert®, Demerol®, Endocet®, Lortab®, OxyContin®, Percodan®, Percocet®, Ritalin®, Strattera®, Vicodin® and Vicoprofen®, which are the property of their respective owners.



The Company|Management|Research & Development|Product Candidates|Investor Relations|Contact Us

© 2004 New River Pharmaceuticals Inc.